CY1117909T1 - Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της

Info

Publication number
CY1117909T1
CY1117909T1 CY20161100799T CY161100799T CY1117909T1 CY 1117909 T1 CY1117909 T1 CY 1117909T1 CY 20161100799 T CY20161100799 T CY 20161100799T CY 161100799 T CY161100799 T CY 161100799T CY 1117909 T1 CY1117909 T1 CY 1117909T1
Authority
CY
Cyprus
Prior art keywords
rosuvastatin
salt
pharmaceutical composition
medoxomil
olmesartane
Prior art date
Application number
CY20161100799T
Other languages
English (en)
Inventor
Hee-Chul Chang
Bok-Ki Kang
Jun-Ku Kim
Of Korea Republic
Original Assignee
Daewoong Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49260650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co., Ltd filed Critical Daewoong Pharmaceutical Co., Ltd
Publication of CY1117909T1 publication Critical patent/CY1117909T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει φαρμακευτική σύνθεση που έχει μορφή μονής δόσης που περιλαμβάνει διαμέρισμα που περιλαμβάνει ολμεσαρτάνη μεδοξομίλη· και διαμέρισμα που περιλαμβάνει ροσουβαστατίνη ή το άλας της, όπου αυτά τα διαμερίσματα είναι τυποποιημένα σε ξεχωριστή μορφή. Στην φαρμακευτική σύνθεση της παρούσας εφεύρεσης, η ολμεσαρτάνη μεδοξομίλη και ροσουβαστατίνη ή το άλας της είναι τυποποιημένα σε μορφή συνδυασμένης δόσης που έχει ξεχωριστά διαμερίσματα, ούτως ώστε να καθίσταται δυνατή η λύση του προβλήματος απορρόφησης-αναστολής που προκύπτει από αλληλεπίδραση φαρμάκων. Επιπροσθέτως, η χρήση ορισμένου (ορισμένων) αποσαθρωτικού (αποσαθρωτικών) καθιστά δυνατή την απόκτηση συνδυασμένου σκευάσματος που είναι βιοϊσοδύναμο με ξεχωριστά σκευάσματα του κάθε φαρμάκου.
CY20161100799T 2012-03-30 2016-08-11 Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της CY1117909T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120032903 2012-03-30
PCT/KR2013/002378 WO2013147462A1 (en) 2012-03-30 2013-03-22 Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Publications (1)

Publication Number Publication Date
CY1117909T1 true CY1117909T1 (el) 2017-05-17

Family

ID=49260650

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100799T CY1117909T1 (el) 2012-03-30 2016-08-11 Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της

Country Status (23)

Country Link
US (1) US20150050333A1 (el)
EP (1) EP2830618B1 (el)
JP (1) JP6122098B2 (el)
KR (2) KR101451081B1 (el)
CN (1) CN104220068B (el)
AU (1) AU2013240846B2 (el)
CA (1) CA2866377C (el)
CL (1) CL2014002581A1 (el)
CY (1) CY1117909T1 (el)
DK (1) DK2830618T3 (el)
ES (1) ES2587912T3 (el)
HK (1) HK1200107A1 (el)
HU (1) HUE030674T2 (el)
IN (1) IN2014MN01919A (el)
LT (1) LT2830618T (el)
MX (1) MX362400B (el)
MY (1) MY166288A (el)
PH (2) PH12014501813A1 (el)
PT (1) PT2830618T (el)
RU (1) RU2616516C2 (el)
SG (2) SG11201405198YA (el)
WO (1) WO2013147462A1 (el)
ZA (1) ZA201407544B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016076280A1 (ja) * 2014-11-11 2016-05-19 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
KR20160096583A (ko) * 2015-01-09 2016-08-16 오토텔릭 엘엘씨 Ａｕｃ에 의한 올메사르탄의 투여 방법
CN106727579A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法
CN105395551A (zh) * 2015-11-19 2016-03-16 哈尔滨圣吉药业股份有限公司 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN106727580A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种阿利沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232556A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
US9989543B2 (en) 2016-01-11 2018-06-05 Autotelic, Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
WO2018009842A1 (en) * 2016-07-08 2018-01-11 Autotelic Llc Methods for rosuvastatin dosing by auc
KR102409102B1 (ko) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 제약 조성물
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
CN113811294B (zh) * 2019-02-26 2023-05-12 株式会社大熊制药 用于治疗或预防高血压和高脂血症的单一剂型药物组合物
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
CN113398086A (zh) * 2021-05-18 2021-09-17 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
CN101478966B (zh) * 2006-06-27 2013-08-21 第一三共株式会社 压缩制剂
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
JP5377317B2 (ja) * 2006-10-30 2013-12-25 ハナル バイオファーマ カンパニー リミテッド 放出性が制御されたアンジオテンシン−ＩＩ−受容体遮断剤とＨＭＧ−ＣｏＡ還元酵素阻害剤の複合組成物
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
CA2671979C (en) * 2006-12-07 2014-02-04 Daiichi Sankyo Company, Limited Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
CN101842096A (zh) * 2007-10-29 2010-09-22 第一三共株式会社 薄膜包衣制剂
US20110009482A1 (en) * 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
EP2253318B1 (en) * 2008-03-13 2014-08-06 Daiichi Sankyo Company, Limited Improvement of dissolvability of preparation containing olmesartan medoxomil
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
US10574932B2 (en) * 2008-07-28 2020-02-25 Fox Digital Enterprises, Inc. System and method of generating subtitling for media
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US8399011B1 (en) * 2012-08-10 2013-03-19 Magnifica Inc. Oral particle compositions containing a core and an acid-soluble coat

Also Published As

Publication number Publication date
CN104220068A (zh) 2014-12-17
EP2830618A4 (en) 2015-08-05
HK1200107A1 (en) 2015-07-31
US20150050333A1 (en) 2015-02-19
ES2587912T3 (es) 2016-10-27
PH12014501813B1 (en) 2014-11-24
RU2014143536A (ru) 2016-05-27
MY166288A (en) 2018-06-25
PH12014501813A1 (en) 2014-11-24
LT2830618T (lt) 2016-09-26
AU2013240846B2 (en) 2017-02-02
CL2014002581A1 (es) 2015-01-09
PT2830618T (pt) 2016-11-04
DK2830618T3 (en) 2016-10-03
KR20130111335A (ko) 2013-10-10
EP2830618A1 (en) 2015-02-04
EP2830618B1 (en) 2016-07-27
WO2013147462A1 (en) 2013-10-03
IN2014MN01919A (el) 2015-07-10
PH12016500420A1 (en) 2017-04-10
AU2013240846A1 (en) 2014-08-28
SG11201405198YA (en) 2014-09-26
CA2866377A1 (en) 2013-10-03
KR101451081B1 (ko) 2014-10-16
MX2014011510A (es) 2014-12-05
HUE030674T2 (en) 2017-06-28
JP2015511635A (ja) 2015-04-20
CA2866377C (en) 2020-02-11
RU2616516C2 (ru) 2017-04-17
JP6122098B2 (ja) 2017-04-26
ZA201407544B (en) 2015-12-23
CN104220068B (zh) 2017-08-04
KR20140085411A (ko) 2014-07-07
SG10201502582PA (en) 2015-05-28
KR101931195B1 (ko) 2018-12-21
MX362400B (es) 2019-01-16

Similar Documents

Publication Publication Date Title
CY1117909T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1119714T1 (el) Ενωσεις αναστολεων
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
EA201792421A1 (ru) Амидозамещенные производные циклогексана
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY1119667T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζινες
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
DOP2015000170A (es) Compuestos químicos
ECSP17069696A (es) Compuestos novedosos
EA201600434A1 (ru) Применение производных бензимидазолпролина